![](/wp-content/uploads/2018/10/p61ctgluTVe4a9RFh26L.png)
$599
GlySens Implantable CGM Trial Completed
The FIGS-2 trial for GlySens’s implantable CGM, Eclipse, has completed according toCT.gov- two and a half years after the originally scheduled completion date of December 2015. The primary endpoint of the 20-subject study was adverse events. FENIX has conducted a headwinds/tailwinds analysis of the Eclipse system in the context of the larger CGM market.